免疫检查点抑制剂的发展概况  

The research progress of the immune checkpoint inhibitors

作　　者：郭子寒 杜琼[1,2,3] 戴贤春 刘莹莹 余波 翟青[1,2,3] 

机构地区：[1]复旦大学上海医学院肿瘤学系,上海200032 [2]复旦大学附属肿瘤医院药剂科,上海200032 [3]复旦大学附属肿瘤医院质子重离子中心,上海201321

出　　处：《上海医药》2018年第5期10-13,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：免疫检查点抑制剂治疗能延长黑素瘤、肺癌、膀胱癌和淋巴瘤等难治性癌症患者的存活期,且不良反应的总发生率较低,给癌症治疗带来了全新的治疗理念。本文简要介绍细胞毒T淋巴细胞相关抗原-4和细胞程序性死亡受体-1/细胞程序性死亡受体配体-1抑制剂的发展概况。Immunotherapy with the inhibitors of immune checkpoint can improve the survival rates of melanoma, lung cancer, bladder cancer, lymphoma and other obstinate carcinoma, and the incidence of adverse events was lower, which can bring in a new concept for tumor treatment. In this paper, we review the latest research processes of cytotoxic T lymphocyte-associated antigen-4 inhibitors and programmed cell death-1/programmed cell death-ligand 1 inhibitors.

关 键 词：肿瘤 免疫治疗 细胞毒T淋巴细胞相关抗原-4 细胞程序性死亡受体-1 细胞程序性死亡受体配体-1 

分 类 号：R979.19[医药卫生—药品]